U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

MedGen UID:
1703107
•Concept ID:
C5205067
•
Neoplastic Process

Definition

Transformed follicular lymphoma to diffuse large B-cell lymphoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Professional guidelines

PubMed

Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F, Gordon LI
Future Oncol 2023 Jan;19(1):19-28. Epub 2023 Jan 18 doi: 10.2217/fon-2022-0774. PMID: 36651471
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD
Clin Lymphoma Myeloma Leuk 2019 Dec;19(12):791-798. Epub 2019 Sep 28 doi: 10.1016/j.clml.2019.09.612. PMID: 31648953
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H
J Natl Compr Canc Netw 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029. PMID: 31200358

Recent clinical studies

Etiology

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
Lancet 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1 doi: 10.1016/S0140-6736(20)31366-0. PMID: 32888407
Clinical and Biological Prognostic Factors in Follicular Lymphoma.
Patel AA, Smith SM
Hematol Oncol Clin North Am 2020 Aug;34(4):647-662. Epub 2020 May 6 doi: 10.1016/j.hoc.2020.02.002. PMID: 32586571
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
CAR T cell therapy for B-cell lymphomas.
Chavez JC, Locke FL
Best Pract Res Clin Haematol 2018 Jun;31(2):135-146. Epub 2018 Apr 11 doi: 10.1016/j.beha.2018.04.001. PMID: 29909914Free PMC Article
Transformed follicular lymphoma.
Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S
Ann Hematol 2018 Jan;97(1):17-29. Epub 2017 Oct 18 doi: 10.1007/s00277-017-3151-2. PMID: 29043381

Diagnosis

Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review.
Zheng W, Xue Q, Sha X, Wang Y, Wang Y, Liu J, Zhang Y, Shi W
Cancer Biol Ther 2021 Dec 2;22(10-12):537-543. Epub 2021 Sep 27 doi: 10.1080/15384047.2021.1967083. PMID: 34570671Free PMC Article
Clinical and Biological Prognostic Factors in Follicular Lymphoma.
Patel AA, Smith SM
Hematol Oncol Clin North Am 2020 Aug;34(4):647-662. Epub 2020 May 6 doi: 10.1016/j.hoc.2020.02.002. PMID: 32586571
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A
Blood Cancer J 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0. PMID: 29895903Free PMC Article
Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.
Wong E, Dickinson M
Curr Oncol Rep 2012 Oct;14(5):424-32. doi: 10.1007/s11912-012-0258-4. PMID: 22865028
Atypical Burkitt's lymphoma transforming from follicular lymphoma.
Hwang YY, Loong F, Chung LP, Chim CS
Diagn Pathol 2011 Jul 8;6:63. doi: 10.1186/1746-1596-6-63. PMID: 21736761Free PMC Article

Therapy

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
Lancet 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1 doi: 10.1016/S0140-6736(20)31366-0. PMID: 32888407
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10 doi: 10.1056/NEJMoa1707447. PMID: 29226797Free PMC Article

Prognosis

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502Free PMC Article
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article
Transformed follicular lymphoma.
Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S
Ann Hematol 2018 Jan;97(1):17-29. Epub 2017 Oct 18 doi: 10.1007/s00277-017-3151-2. PMID: 29043381
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10 doi: 10.1056/NEJMoa1707447. PMID: 29226797Free PMC Article

Clinical prediction guides

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Development of diffuse large B-cell lymphoma from duodenal type follicular lymphoma: a retrospective study of 23 cases.
Saburi M, Kondo Y, Ogata M, Soga Y, Abe M, Takano K, Kohno K, Nagai T, Nakayama T
Int J Hematol 2020 Nov;112(5):658-665. Epub 2020 Aug 1 doi: 10.1007/s12185-020-02957-z. PMID: 32740764
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY, Zhou J, Young KH
Blood 2018 Jan 4;131(1):68-83. Epub 2017 Nov 8 doi: 10.1182/blood-2017-07-740993. PMID: 29118007Free PMC Article
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF
J Clin Oncol 2017 Mar 10;35(8):826-833. Epub 2017 Jan 17 doi: 10.1200/JCO.2016.70.4320. PMID: 28095146Free PMC Article
Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.
Wong E, Dickinson M
Curr Oncol Rep 2012 Oct;14(5):424-32. doi: 10.1007/s11912-012-0258-4. PMID: 22865028

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...